- Home
- FENC vs HRTX Comparison
FENC vs HRTX Comparison
Compare FENC & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- HRTX
- Stock Information
- Founded
- FENC 1996
- HRTX 1983
- Country
- FENC United States
- HRTX United States
- Employees
- FENC N/A
- HRTX N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- FENC Health Care
- HRTX Health Care
- Exchange
- FENC Nasdaq
- HRTX Nasdaq
- Market Cap
- FENC 225.4M
- HRTX 206.9M
- IPO Year
- FENC 2001
- HRTX 1987
- Fundamental
- Price
- FENC $9.05
- HRTX $1.33
- Analyst Decision
- FENC Strong Buy
- HRTX Strong Buy
- Analyst Count
- FENC 2
- HRTX 2
- Target Price
- FENC $13.50
- HRTX $4.50
- AVG Volume (30 Days)
- FENC 67.3K
- HRTX 2.6M
- Earning Date
- FENC 11-06-2025
- HRTX 08-08-2025
- Dividend Yield
- FENC N/A
- HRTX N/A
- EPS Growth
- FENC N/A
- HRTX N/A
- EPS
- FENC N/A
- HRTX N/A
- Revenue
- FENC $33,302,000.00
- HRTX $149,694,000.00
- Revenue This Year
- FENC $0.96
- HRTX $10.62
- Revenue Next Year
- FENC $51.71
- HRTX $12.99
- P/E Ratio
- FENC N/A
- HRTX N/A
- Revenue Growth
- FENC N/A
- HRTX 9.78
- 52 Week Low
- FENC $3.96
- HRTX $1.04
- 52 Week High
- FENC $9.42
- HRTX $2.68
- Technical
- Relative Strength Index (RSI)
- FENC 58.08
- HRTX 35.87
- Support Level
- FENC $8.73
- HRTX $1.27
- Resistance Level
- FENC $9.29
- HRTX $1.35
- Average True Range (ATR)
- FENC 0.32
- HRTX 0.06
- MACD
- FENC 0.05
- HRTX 0.02
- Stochastic Oscillator
- FENC 86.06
- HRTX 38.89
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.